| Ginseng = adaptogenic herbal root from the genus Panax; main species: Asian ginseng (Panax ginseng) and American ginseng (Panax quinquefolius). Active constituents: ginsenosides (Rb1, Rg1, Rg3, Rh2), polysaccharides, and other saponins.
Primary mechanisms (conceptual rank):
1) Multi-pathway signaling modulation (PI3K/Akt, MAPK, NF-κB; isoform-dependent).
2) Redox regulation (bidirectional ROS modulation; NRF2 interaction).
3) Anti-inflammatory and immunomodulatory effects.
4) Anti-proliferative and pro-apoptotic effects in cancer (notably Rg3, Rh2; dose-dependent).
5) Neurotrophic and cholinergic modulation (BDNF, ACh support).
PK / bioavailability: ginsenosides have variable oral absorption; gut microbiota convert to active metabolites (e.g., Compound K); plasma levels generally lower than many in-vitro doses.
In-vitro vs systemic exposure: many cancer studies use ≥10–100 µM; achievable plasma concentrations after oral dosing are typically lower and metabolite-driven.
Clinical evidence status: supportive oncology (fatigue reduction) supported by RCTs; direct anti-cancer efficacy largely preclinical; cognitive and fatigue benefits better substantiated.
Ginseng (Panax ginseng) – This herb has been studied for its ability to enhance the immune system.
-Antioxidant Properties: Ginseng contains ginsenosides, which have antioxidant properties.
-Immune System Support
-Inhibition of Tumor Growth
-Chemopreventive Effects
-Synergistic Effects with Cancer Treatments: ginseng may enhance the effectiveness of certain cancer treatments, such as chemotherapy, and may help reduce side effect
Dose: Standardized Extract:
Dosage: extract containing 4-7% ginsenosides 200-400mg/d
Dried Root:1-2g/d
Tea: 1-2g dried root, 1-3x/d
Ginseng (Panax spp.) — Cancer-Relevant Pathways
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
PI3K/Akt / MAPK signaling |
↓ proliferation (isoform-dependent) |
↔ / adaptive support |
R→G |
Growth signaling attenuation |
Ginsenosides Rg3/Rh2 most studied; context- and tumor-type dependent. |
| 2 |
Apoptosis (caspase / mitochondrial) |
↑ (dose-dependent) |
↔ / protective |
R→G |
Pro-apoptotic signaling |
Mitochondrial depolarization reported; supra-physiologic concentrations common in vitro. |
| 3 |
ROS modulation |
↑ (high concentration) / ↓ (adaptive) |
↓ |
P→R |
Redox modulation |
Bidirectional: pro-oxidant cytotoxicity in tumors at high dose; antioxidant in normal cells. |
| 4 |
NF-κB / inflammation |
↓ |
↓ |
R→G |
Anti-inflammatory |
Reduces pro-tumor inflammatory microenvironment signals. |
| 5 |
Angiogenesis (VEGF) |
↓ (preclinical) |
↔ |
G |
Anti-angiogenic |
Reported particularly with Rg3; human oncologic outcome data limited. |
| 6 |
NRF2 axis |
↔ / ↑ (adaptive) |
↑ |
G |
Antioxidant enzyme induction |
Protective in normal tissues; tumor resistance context-dependent. |
| 7 |
Clinical Translation Constraint |
— |
— |
— |
Adjunct role |
RCTs support fatigue reduction in cancer patients; direct anti-tumor efficacy not established. |
TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
Ginseng (Panax spp.) — Alzheimer’s Disease–Relevant Axes
| Rank |
Pathway / Axis |
Cells (neurons/glia) |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
BDNF / neuroplasticity |
↑ |
G |
Neurotrophic support |
Rg1 and metabolites reported to enhance BDNF signaling; supports cognition in mild impairment models. |
| 2 |
Cholinergic modulation |
↑ (mild) |
R→G |
ACh support |
May increase ACh release or inhibit AChE modestly; relevance additive to standard therapy unclear. |
| 3 |
Neuroinflammation (NF-κB) |
↓ |
R→G |
Microglial modulation |
Reduces pro-inflammatory cytokines in animal models. |
| 4 |
ROS / oxidative stress |
↓ |
P→R |
Antioxidant support |
Induces antioxidant enzymes; may protect against Aβ-induced oxidative injury. |
| 5 |
Aβ processing |
↓ (preclinical) |
G |
Reduced amyloid burden |
Animal studies suggest modulation of APP processing; human AD RCT data limited. |
| 6 |
Clinical Translation Constraint |
— |
— |
Modest cognitive benefit |
Small human trials suggest mild cognitive improvement; not disease-modifying. |
TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
|